• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by ATAI Life Sciences N.V. (Amendment)

    2/13/24 4:29:52 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ATAI alert in real time by email
    SC 13G/A 1 d787948dsc13ga.htm SC 13G/A SC 13G/A

     

     

    Securities and Exchange Commission

    Washington, D.C. 20549

     

     

    Schedule 13G

    (Rule 13d-102)

    Information to be Included in Statements Filed Pursuant

    to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed

    Pursuant to § 240.13d-2

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No. 2)*

     

     

    ATAI Life Sciences N.V.

    (Name of Issuer)

    Common Shares

    (Title of Class of Securities)

    N0731H103

    (CUSIP Number)

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. N0731H103    Schedule 13G    Page 1 of 10

     

     1   

    Names of Reporting Persons

     

    Apeiron Investment Group Ltd.

     2   

    Check the Appropriate Box if a Member of a Group

    (a) ☐  (b) ☐

     

     3   

    SEC Use Only

     

     4   

    Citizenship or Place of Organization

     

    Malta

    Number of Shares Beneficially  Owned by Each Reporting Person

    With

        5   

    Sole Voting Power

     

    0

        6   

    Shared Voting Power

     

    33,885,999

        7   

    Sole Dispositive Power

     

    0

        8   

    Shared Dispositive Power

     

    33,885,999

     9   

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    33,885,999

    10   

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    Not Applicable

    11   

    Percent of Class Represented by Amount in Row 9

     

    20.1%

    12   

    Type of Reporting Person

     

    CO


    CUSIP No. N0731H103    Schedule 13G    Page 2 of 10

     

     1   

    Names of Reporting Persons

     

    Apeiron Presight Capital Fund II, L.P.

     2   

    Check the Appropriate Box if a Member of a Group

    (a) ☐  (b) ☐

     

     3   

    SEC Use Only

     

     4   

    Citizenship or Place of Organization

     

    Delaware

    Number of Shares Beneficially  Owned by Each Reporting Person

    With

        5   

    Sole Voting Power

     

    0

        6   

    Shared Voting Power

     

    1,799,302

        7   

    Sole Dispositive Power

     

    0

        8   

    Shared Dispositive Power

     

    1,799,302

     9   

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,799,302

    10   

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    Not Applicable

    11   

    Percent of Class Represented by Amount in Row 9

     

    1.1%

    12   

    Type of Reporting Person

     

    PN


    CUSIP No. N0731H103    Schedule 13G    Page 3 of 10

     

     1   

    Names of Reporting Persons

     

    Presight Capital Management I, L.L.C.

     2   

    Check the Appropriate Box if a Member of a Group

    (a) ☐  (b) ☐

     

     3   

    SEC Use Only

     

     4   

    Citizenship or Place of Organization

     

    Delaware

    Number of Shares Beneficially  Owned by Each Reporting Person

    With

        5   

    Sole Voting Power

     

    0

        6   

    Shared Voting Power

     

    1,799,302

        7   

    Sole Dispositive Power

     

    0

        8   

    Shared Dispositive Power

     

    1,799,302

     9   

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,799,302

    10   

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    Not Applicable

    11   

    Percent of Class Represented by Amount in Row 9

     

    1.1%

    12   

    Type of Reporting Person

     

    OO


    CUSIP No. N0731H103    Schedule 13G    Page 4 of 10

     

     1   

    Names of Reporting Persons

     

    Fabian Hansen

     2   

    Check the Appropriate Box if a Member of a Group

    (a) ☐  (b) ☐

     

     3   

    SEC Use Only

     

     4   

    Citizenship or Place of Organization

     

    Federal Republic of Germany

    Number of Shares Beneficially  Owned by Each Reporting Person

    With

        5   

    Sole Voting Power

     

    0

        6   

    Shared Voting Power

     

    1,799,302

        7   

    Sole Dispositive Power

     

    0

        8   

    Shared Dispositive Power

     

    1,799,302

     9   

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,799,302

    10   

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    Not Applicable

    11   

    Percent of Class Represented by Amount in Row 9

     

    1.1%

    12   

    Type of Reporting Person

     

    IN


    CUSIP No. N0731H103    Schedule 13G    Page 5 of 10

     

     1   

    Names of Reporting Persons

     

    Christian Angermayer

     2   

    Check the Appropriate Box if a Member of a Group

    (a) ☐  (b) ☐

     

     3   

    SEC Use Only

     

     4   

    Citizenship or Place of Organization

     

    Federal Republic of Germany

    Number of Shares Beneficially  Owned by Each Reporting Person

    With

        5   

    Sole Voting Power

     

    0

        6   

    Shared Voting Power

     

    33,885,999

        7   

    Sole Dispositive Power

     

    0

        8   

    Shared Dispositive Power

     

    33,885,999

     9   

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    33,885,999

    10   

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    Not Applicable

    11   

    Percent of Class Represented by Amount in Row 9

     

    20.1%

    12   

    Type of Reporting Person

     

    IN


    CUSIP No. N0731H103    Schedule 13G    Page 6 of 10

     

    ITEM 1.    (a)    Name of Issuer:
          ATAI Life Sciences N.V. (the “Issuer”).
       (b)    Address of Issuer’s Principal Executive Offices:
          ATAI Life Sciences N.V., Wallstraße 16, 10179, Berlin, Germany.
    ITEM 2.    (a)    Name of Person Filing:
         

    Each of the following is hereinafter individually referred to as a “Reporting Person” and collectively as the “Reporting Persons.” This statement is filed on behalf of:

         

    Apeiron Investment Group Ltd. (“Apeiron”);

         

    Apeiron Presight Capital Fund II, L.P. (“Presight II”);

         

    Presight Capital Management I, L.L.C. (“Presight Management”);

         

    Fabian Hansen; and

         

    Christian Angermayer.

       (b)    Address or Principal Business Office:
         

    The principal business address of Apeiron and Mr. Angermayer is 66 & 67 Amery Street, SLM1707, Sliema, Malta. The principal business address of each of the remaining Reporting Persons is 440 N Barranca Ave #3391 Covina, CA 91723 USA.

       (c)    Citizenship of each Reporting Person is:
         

    Presight II and Presight Management are organized under the laws of the State of Delaware. Apeiron is organized under the laws of Malta. Each of Messrs. Hansen and Angermayer is a German citizen.

       (d)    Title of Class of Securities:
         

    Common shares, par value €0.1 per share (“Common Shares”).

       (e)    CUSIP Number:
         

    N0731H103

    ITEM 3.      
       Not applicable.


    CUSIP No. N0731H103    Schedule 13G    Page7 of 10

     

    ITEM 4.    Ownership.
       (a-c)
      

    The ownership information presented below represents beneficial ownership of the Common Shares of the Issuer as of December 31, 2023, based upon 166,010,476 shares of Common Shares outstanding as of November 6, 2023, as disclosed in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 14, 2023.

     

    Reporting Person   

    Amount

    beneficially 

    owned

        

    Percent

    of class:

        Sole power
    to vote or to
    direct the
    vote:
         Shared power
    to vote or to
    direct the vote:
        

    Sole
    power to
    dispose or
    to direct
    the
    disposition

    of:

        

    Shared

    power to

    dispose or

    to direct

    the

    disposition

    of:

     

    Apeiron Investment Group Ltd.

         33,885,999        20.1 %      0        33,885,999        0        33,885,999  

    Apeiron Presight Capital Fund II, L.P.

         1,799,302        1.1 %      0        1,799,302        0        1,799,302  

    Presight Capital Management I, L.L.C.

         1,799,302        1.1 %      0        1,799,302        0        1,799,302  

    Fabian Hansen

         1,799,302        1.1 %      0        1,799,302        0        1,799,302  

    Christian Angermayer

         33,885,999        20.1 %      0        33,885,999        0        33,885,999  

     

      

    Presight II is the record holder of 1,799,302 Common Shares. Apeiron and Fabian Hansen are the managing members of Presight Management, which is the general partner of Presight II. As a result, each of Apeiron, Mr. Hansen and Presight Management may be deemed to share beneficial ownership of the securities held by Presight II.

      

    In addition, Apeiron is the record holder of 29,719,497 Common Shares and may be deemed to own an additional 2,367,200 Common Shares underlying convertible notes of the Issuer. Christian Angermayer is the majority shareholder of Apeiron and may be deemed to share beneficial ownership of the securities beneficially owned by Apeiron.

    ITEM 5.    Ownership of Five Percent or Less of a Class.
       Not applicable.
    ITEM 6.    Ownership of More than Five Percent on Behalf of Another Person.
       Not applicable.
    ITEM 7.    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.
       Not applicable.


    CUSIP No. N0731H103    Schedule 13G    Page 8 of 10

     

    ITEM 8.    Identification and Classification of Members of the Group.
       Not applicable.
    ITEM 9.    Notice of Dissolution of Group.
       Not applicable.
    ITEM 10.    Certification.
       Not applicable.


    CUSIP No. N0731H103    Schedule 13G    Page 9 of 10

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 13, 2024
    Apeiron Investment Group, Ltd.
    By:   /s/ Julien Höfer
    Name:   Julien Höfer
    Title:   Director
    Apeiron Presight Capital Fund II, L.P.
    By:   Presight Capital Management I, L.L.C., its general partner
    By:   /s/ Fabian Hansen
    Name:   Fabian Hansen
    Title:   Managing Member
    Presight Capital Management I, L.L.C.
    By:   /s/ Fabian Hansen
    Name:   Fabian Hansen
    Title:   Managing Member
    Fabian Hansen
    /s/ Fabian Hansen
    Christian Angermayer
    /s/ Christian Angermayer


    CUSIP No. N0731H103    Schedule 13G    Page 10 of 10

     

    LIST OF EXHIBITS

     

    Exhibit No.

      

    Description

    99    Joint Filing Agreement (previously filed).
    Get the next $ATAI alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATAI

    DatePrice TargetRatingAnalyst
    10/13/2025$12.00Buy
    Needham
    7/29/2025$14.00Outperform
    Oppenheimer
    4/4/2025Buy
    Berenberg
    11/18/2024$15.00 → $10.00Buy
    H.C. Wainwright
    4/3/2024$6.00Hold → Buy
    Maxim Group
    11/1/2022$18.00Buy
    Loop Capital
    11/30/2021$25.00Buy
    Maxim Group
    11/22/2021$40.00 → $50.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $ATAI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Apeiron Investment Group Ltd. bought $19,000,000 worth of shares (8,675,799 units at $2.19) (SEC Form 4)

    4 - ATAI Life Sciences N.V. (0001840904) (Issuer)

    8/18/25 6:00:05 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Apeiron Investment Group Ltd. bought $2,520,000 worth of shares (1,800,000 units at $1.40) (SEC Form 4)

    4 - ATAI Life Sciences N.V. (0001840904) (Issuer)

    3/24/25 5:00:18 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Apeiron Investment Group Ltd. bought $22,755,008 worth of shares (10,835,718 units at $2.10) (SEC Form 4)

    4 - ATAI Life Sciences N.V. (0001840904) (Issuer)

    2/19/25 6:00:05 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATAI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Needham initiated coverage on atai Life Sciences N.V. with a new price target

    Needham initiated coverage of atai Life Sciences N.V. with a rating of Buy and set a new price target of $12.00

    10/13/25 8:51:27 AM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer initiated coverage on atai Life Sciences N.V. with a new price target

    Oppenheimer initiated coverage of atai Life Sciences N.V. with a rating of Outperform and set a new price target of $14.00

    7/29/25 7:39:06 AM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Berenberg initiated coverage on atai Life Sciences N.V.

    Berenberg initiated coverage of atai Life Sciences N.V. with a rating of Buy

    4/4/25 8:27:07 AM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATAI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Hershberg Robert

    4 - Atai Beckley N.V. (0001840904) (Issuer)

    11/6/25 8:54:40 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Feilding-Mellen Cosmo was granted 7,702,990 shares (SEC Form 4)

    4 - Atai Beckley N.V. (0001840904) (Issuer)

    11/6/25 8:49:06 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Braunstein Scott

    4 - Atai Beckley N.V. (0001840904) (Issuer)

    11/6/25 8:45:17 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATAI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Enhanced Fortifies Executive Leadership Team & Board of Directors

    – Co-Founder Maximilian Martin Appointed CEO – – Co-Founder Christian Angermayer Appointed Executive Chairman – – Jim Murren to join Board of Directors – – Company Appoints Sid Banthiya Chief Financial Officer; Promotes Alex Lopez to Chief Brand Officer and Rick Adams to Chief Sporting Officer – – Names Chris Jones Chief Communications Officer – NEW YORK, Nov. 19, 2025 /PRNewswire/ -- Enhanced, the elite sports competition and performance products company committed to giving athletes and people alike the ability to optimize their health, performance and recovery, today announced that it has fortified its executive leadership team and its board of directors.  Enhanced Fortifies Executive Lea

    11/19/25 7:32:00 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AtaiBeckley to Participate in the Jefferies Global Healthcare Conference in London

    NEW YORK and AMSTERDAM, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Atai Beckley N.V. (NASDAQ:ATAI) ("AtaiBeckley" or "Company"), a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting and convenient mental health treatments, today announced that Srinivas Rao, M.D., Ph.D., Co-Founder and Chief Executive Officer, and Kevin Craig, M.D., Chief Medical Officer, are scheduled to participate in the Jefferies Global Healthcare Conference in London, UK. Details of the company's participation: Format: Fireside chat and 1x1 investor meetingsDate and Time: Fireside chat on Thursday, November 20 at 11:30 A.M. GMT/ 6:30 A.M. ETWebcast link: He

    11/13/25 9:00:00 AM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AtaiBeckley Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

    BPL-003 (mebufotenin benzoate nasal spray) granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for treatment-resistant depression (TRD) Reported positive topline data from the Phase 2b open-label extension (OLE) study of BPL-003 showing the potential added and sustained antidepressant effects following a second dose in patients with TRD Reported positive open-label Phase 2a data demonstrating improved outcomes with a two-dose induction regimen of BPL-003 in patients with TRDAn End-of-Phase 2 meeting is scheduled with the FDA for BPL-003, anticipate providing guidance on the Phase 3 clinical program in the first quarter of 2026Completed enrollment in the ex

    11/12/25 7:00:00 AM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATAI
    SEC Filings

    View All

    SEC Form 10-Q filed by Atai Beckley N.V

    10-Q - Atai Beckley N.V. (0001840904) (Filer)

    11/12/25 4:11:38 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Atai Beckley N.V filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Atai Beckley N.V. (0001840904) (Filer)

    11/12/25 7:19:28 AM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ATAI Life Sciences N.V. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - ATAI Life Sciences N.V. (0001840904) (Filer)

    11/5/25 8:36:27 AM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATAI
    Leadership Updates

    Live Leadership Updates

    View All

    atai Life Sciences Announces Key Leadership Appointments as it Advances its Pipeline of Novel Psychedelic Therapeutics for Mental Health

    - Srinivas Rao M.D., Ph.D. succeeds as sole Chief Executive Officer- Kevin Craig, M.D. promoted to Chief Medical Officer- Glenn Short, Ph.D. promoted to Chief Scientific Officer- Gerd Kochendoerfer, Ph.D. joins as Chief Operating Officer NEW YORK and BERLIN, Jan. 10, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced key leadership appointments to advance its goal of delivering novel mental health therapeutics. Srinivas Rao M.D., Ph.D., has assumed the role of sole Chief Executive Officer (CEO), joined by the promotions of Kevin Craig, M.D.

    1/10/25 7:00:00 AM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    atai Life Sciences Strengthens Board with Appointment of Two New Independent Directors

    NEW YORK and BERLIN, May 23, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the appointment of Scott Braunstein, M.D., and Laurent Fischer, M.D., as independent directors of atai's supervisory board ("Board") subject to applicable legal requirements. Scott Braunstein, M.D., is the Chief Executive Officer ("CEO") and Chairman of Marinus Pharmaceuticals, Inc. He is an operating partner at Aisling Capital and serves on the Board of Directors at both Caribou Biosciences, Inc. and Trevena Inc. Previously, Dr. Braunstein was Chief Operati

    5/23/24 7:00:00 AM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    atai Life Sciences Appoints Anne Johnson as Chief Financial Officer

    NEW YORK and BERLIN, Feb. 06, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company") today announced that Anne Johnson, the Company's interim Chief Financial Officer since October 2023 and Chief Accounting Officer since August 2022, has been named Chief Financial Officer (CFO). Anne succeeds Stephen Bardin as the Company's CFO while Stephen will continue in an advisory role until March 31, 2024 to support the transition. "Anne has been an integral member of our team for over three years and has demonstrated the executive leadership, financial acumen, and track record to lead our financial organization with excellence," said atai Co-founder and Chief Executive Off

    2/6/24 5:00:31 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATAI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by ATAI Life Sciences N.V.

    SC 13D/A - ATAI Life Sciences N.V. (0001840904) (Filed by)

    9/27/24 7:56:26 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by ATAI Life Sciences N.V. (Amendment)

    SC 13D/A - ATAI Life Sciences N.V. (0001840904) (Filed by)

    5/3/24 4:06:02 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by ATAI Life Sciences N.V. (Amendment)

    SC 13D/A - ATAI Life Sciences N.V. (0001840904) (Filed by)

    3/12/24 9:30:31 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATAI
    Financials

    Live finance-specific insights

    View All

    AtaiBeckley Announces Positive Topline Data from the Phase 2b Open-Label Extension Study of BPL-003, Supporting Safety and Efficacy of a Second Dose in Patients with Treatment-Resistant Depression

    A 12 mg dose of BPL-003 (mebufotenin benzoate nasal spray) administered eight weeks after an initial 12 mg, 8 mg or 0.3 mg dose in the core study of the Phase 2b clinical trial produced additional rapid, clinically meaningful antidepressant effects that were sustained for up to eight weeksPatients who received an active dose of BPL-003 in the core study of the Phase 2b clinical trial (either 8 mg or 12 mg) met response and remission criteria for depression at increased rates after receiving a 12 mg dose in the OLE study, with 63% in response and 48% in remission at Week 8 in the OLE study (Week 16 of the Phase 2b clinical trial)An End-of-Phase 2 meeting has been scheduled with the U.S. Food

    11/10/25 7:00:00 AM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression

    Study met its primary and all key secondary endpoints, and BPL-003 demonstrated rapid, robust and durable antidepressant effects with a single doseBoth 8 mg and 12 mg single doses of BPL-003 showed statistically significant and clinically meaningful reductions in depressive symptoms at all time points of the study compared to a 0.3 mg low-dose active control out to Week 8BPL-003 was generally well-tolerated at all doses, with 99% of treatment-emergent adverse events being mild or moderate, and no drug-related serious adverse events or suicide-related safety signalsMajority of patients deemed ready for discharge at the 90 minutes post-dose assessment, which suggests BPL-003 could fit within t

    7/1/25 6:00:00 AM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    atai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies

    Strategic combination establishes a market-leading mental health company with a pipeline that includes potentially transformative, rapid-acting psychedelic assets differentiated by their convenient route of administration and short time-in-clinicCombined company will operate under the name atai Beckley with a joint leadership team and Board that leverage the deep psychedelic, drug development and CNS expertise within both organizationsTopline data from the Phase 2b study of BPL-003 in patients with treatment-resistant depression (TRD) is expected in mid-2025 - the largest controlled trial of mebufotenin (5-MeO-DMT) and the first and only controlled trial to investigate mebufotenin in the U.S

    6/2/25 6:00:00 AM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care